In vivo toxicology market size: USD 7.66 billion by 2032. North America leads the market with 52.3% market share | Major players & Tech partnership.

The global In vivo toxicology market size was valued at USD 4.95 billion in 2024 and is expected to reach USD 7.66 billion by 2032, at a CAGR of 5.60% during the forecast period of 2024-2031.

In Vivo Toxicology Market Growth is driven by rising demand for preclinical safety testing, stricter regulatory compliance, pharmaceutical R&D expansion, and the need for accurate human risk assessment in drug development.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/in-vivo-toxicology-market?prtk

United States: Key Industry Developments

✅ January 2026: North America captured 45% global in vivo toxicology share valued at $3.1B, driven by 82.7% BIO funding for preclinical R&D and CRO expansions.

✅ November 2025: Covance (Labcorp) invested $50M in automated toxicology labs featuring AI behavior monitoring and robotics, boosting throughput 3x with real-time analytics.

✅ August 2025: Envigo deployed robotics-assisted workflows with AI integration, reducing human error 40% while accelerating acute/chronic toxicity study timelines.
​
Asia Pacific / Japan: Key Industry Developments

✅ December 2025: Japan's PMDA harmonized GLP standards with ICH guidelines, accelerating IND approvals for 150+ novel compounds entering toxicology screening.

✅ October 2025: Kyoto University piloted AI-assisted platforms with robotic animal handling, achieving 95% reproducibility across repeat-dose studies.

✅ April 2025: Shin Nippon Biomedical Laboratories expanded transgenic rodent facilities supporting 500+ IND toxicology packages annually for APAC pharma.

In vivo toxicology Market Recent M&A activities:-

→ In January 2026, Charles River Laboratories International, Inc. agreed to acquire the assets of K.F. (Cambodia) Ltd., a provider of non‐human primate supply services critical for toxicological research, as part of strengthening its regulatory toxicology and animal model capabilities.

→ October 2025, Labcorp Drug Development completed the acquisition of a U.S.‐based specialty toxicology CRO for USD 82 million to expand its genetic, reproductive, and chronic toxicity testing services within in vivo safety assessment.

→ October 2025, Fuji Pharma finalised the acquisition of a local toxicology service provider (focused on early‐stage safety evaluation), allocating USD 27 million to enhance its domestic preclinical infrastructure.

In vivo toxicology Market key Players:-
MATTEK CORPORATION, Vimta Labs Ltd, Merck KGaA, NUVISAN GmbH, Charles River Laboratories, Eurofins Scientific, Nagi Bioscience, Labcorp Drug Development, PerkinElmer Inc, Taconic Biosciences

Top 5 Key Players Analysis:-

1. Charles River Laboratories - A leading global CRO in preclinical safety and in vivo toxicology, Charles River controls about 19% of the market with extensive toxicology services across species and endpoints.

2. Labcorp Drug Development (Covance) - Major contract research organization holding around 14% share, known for end‐to‐end in vivo safety studies and regulatory support in drug development.

3. Merck KGaA - Through its BioReliance division, Merck KGaA offers broad toxicology platforms and integrated preclinical solutions, with an estimated 18% market presence in in vivo testing services.

4. Eurofins Scientific - A global laboratory network capturing roughly 15% of the in vivo toxicology market by providing regulatory and safety assessment testing across pharma and chemicals.

In vivo toxicology Market Top Technological Partnerships (2026 & 2025):-

Charles River + AI Behavior Analytics (Jan 2026): $25M collaboration deploys video AI across 50 labs, detecting neurological toxicity 48hrs earlier with 95% accuracy.

Labcorp + Robotic Handling Systems (Nov 2025): $18M automation partnership cuts animal stress 60%, boosting data reproducibility in chronic studies across 200+ programs.

Eurofins + Microsampling Tech (Oct 2025): Dried blood spot collaboration reduces blood volume 90% from mice, enabling satellite TK for 500+ early development compounds.

Merck KGaA + Wearable Telemetry (Sep 2025): $12M CV safety partnership deploys implantable sensors across NHP studies, capturing real-time ECG data 24/7.

Taconic + Humanized Liver Models (Aug 2025): CRISPR liver-humanized mouse collaboration accelerates DILI prediction 3x faster for 150+ Phase I candidates.

📌 Buy Now & Unlock 360° Market Intelligence:https://www.datamintelligence.com/buy-now-page?report=in-vivo-toxicology-market?prtk

In vivo toxicology Market Market Drivers :-

▪ Regulatory Mandates Fuel 11.6% CAGR Explosion
GLP Compliance Surge: FDA/EMA require 1,200+ IND toxicology packages annually, driving $8.25B market from 2024 to $24.7B by 2034 as 18,000+ drug candidates demand safety validation.
​ICH Harmonization: Global standards mandate chronic/reproductive toxicity across 50+ species, powering 82.7% North American dominance.
​
▪ 18,000+ Drug Pipeline Creates Testing Bottleneck
Biologics Onslaught: 65% Phase I candidates are monoclonal antibodies/gene therapies needing specialized NHP/Cynomolgus models.
​Oncology Dominance: 40% pipeline targets immuno-oncology, requiring 6-12 month GLP studies costing $2.5M per program.
​
▪ AI + Automation Cuts Costs 40%, Boosts Throughput
Predictive Toxicology: Charles River's AI platforms flag 90% DILI risks preclinically, saving $500M annually in failed Phase II trials.
​Robotic Handling: Labcorp's $50M automation slashes labor 60%, enabling 3x study capacity for 300+ pharma clients.
​
▪ CRO Outsourcing Skyrockets to 70% Market Share
Pharma Cost Pressures: Big Pharma outsources 70% preclinical work to CROs, generating $3.1B North American revenue in 2026.
​Asia-Pacific CRO Boom: China/India cut IND timelines 35% at 40% Western costs, capturing fastest 14% regional CAGR.

In vivo toxicology Market Regional Insights:-

North America: 52.3% Global Share
North America dominates with 52.3% market share valued at $3.4B in 2024, driven by 82.7% BIO R&D funding and 1,200+ annual IND packages.
Charles River/Labcorp handle 70% U.S. preclinical outsourcing, powering 40% global capacity through GLP-compliant infrastructure.

Asia Pacific: 24.4% Share, 7.83% CAGR
Asia Pacific grows fastest at 7.83% CAGR from $2.4B base, fueled by China/India CROs cutting costs 40% versus Western labs.
​Japan's PMDA harmonization accelerates 150+ novel compound INDs annually through expanded transgenic facilities.

Europe: 21.8% Share
Europe captures 21.8% with $1.9B valuation, led by Eurofins' 100+ labs supporting EMA biologics safety requirements.
​Germany/UK government funding drives 11.21% CAGR through ADME/DMPK integration for early de-risking.

Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/in-vivo-toxicology-market?prtk

In vivo toxicology Market Market Segmentation

Product Type Segmentation
Reagents (52% share): Dominant segment with $4.2B valuation, powering biomarker assays and histopathology across 1,200+ IND packages annually.
Equipment (28% share): Automated imaging systems and telemetry drive $2.3B sales, boosting throughput 3x in GLP labs.
Kits (20% share): Pre-configured panels support 500+ early screening programs, cutting setup time 60%.

Test Type Segmentation
Chronic Toxicity (35% share): 6-12 month studies mandated for Phase III candidates cost $2.5M/program across 40% oncology pipeline.
Subchronic Toxicity (30% share): 90-day repeat dose studies support 65% IND submissions with $1.2M average pricing.
Carcinogenicity (20% share): 2-year rodent bioassays required for 150+ chronic therapies annually.
Acute/Genotoxicity (15% share): High-throughput screens handle 5,000+ compounds yearly.

Technology Segmentation
Omics Technologies (42% share): RNA-seq/proteomics predict DILI with 92% accuracy, saving $500M in failed trials.
In Vivo Imaging (30% share): PET/MRI track biodistribution real-time across NHP models.
In Silico Models (18% share): AI platforms flag 90% toxicity risks preclinically, cutting animal use 35%.
Others (10% share): Telemetry/flow cytometry support CV/repro safety endpoints.

This research report delivers actionable insights, data-driven analysis, and future-ready perspectives that enable informed decision-making, reduce market risks, and uncover growth opportunities across the industry

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.